Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment (CMT1A-HOME)
Study of the Relationship Between Clinical and Functional Characteristics of Patients With CMT1A Disease and Their Level of Physical Activity at Home Measured Using Portable Electronic Sensors
Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.
This research will:
In the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel "Nano-Cur" treatment currently under development.
Aperçu de l'étude
Statut
Description détaillée
Peripheral neuropathies are frequent conditions affecting peripheral nerves with highly varied etiologies. Among genetic causes, Charcot-Marie-Tooth (CMT) disease is the leading hereditary neuropathy, with approximately 26,000 patients in France. The most frequent form, CMT1A, is caused by a duplication of the PMP22 gene, leading to chronic progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset in childhood and significant impact on quality of life.
No specific pharmacological treatment exists for CMT1A. The CMT-FOM scale (Mandarakas et al., 2024, Neurology, 102: e207963) constitutes the reference for functional evaluation, but requires lengthy evaluation and a specialized technical platform, making it unsuitable for routine outpatient consultations. Furthermore, punctual evaluations may be biased by external factors (fatigue, mood, motivation) without faithfully reflecting the patient's daily neurological status.
Non-invasive wearable physical activity sensors offer a promising alternative, enabling repeated and ecologically valid measurements directly at home and over prolonged periods. This study aims to assess whether such ambulatory sensors can evaluate functional impairments in CMT1A patients equivalently to a comprehensive CMT-FOM evaluation.
The study will be conducted among CMT1A patients followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges), in partnership with the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation (CHU de Limoges). It represents a collaborative effort between research units NeurIT (UR20218) and HAVAE (UR20217).
This project also forms part of the broader development of the "Nano-Cur" therapeutic compound (NeurIT/LABCiS collaboration), having led to a national and international patent filing and the creation of the start-up Curlim (AFM-Téléthon/AVRUL support).
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Maxence COMPAGNAT, Pr
- Numéro de téléphone: 05 55 05 65 18
- E-mail: maxence.compagnat@chu-limoges.fr
Sauvegarde des contacts de l'étude
- Nom: Simon FRACHET, Dr
- E-mail: simon.frachet@chu-limoges.fr
Lieux d'étude
-
-
-
Limoges, France, 87042
- CHU de Limoges
-
Contact:
- sandra JUGE, Dr
- Numéro de téléphone: 05 55 05 64 14
- E-mail: sandra.juge@chu-limoges.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years
- Genetically confirmed diagnosis of CMT1A (PMP22 duplication on chromosomal analysis)
- Followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges) and/or having undergone gait analysis at the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation, CHU de Limoges
- Ability to walk independently (with or without walking aids)
- Informed consent obtained
- Affiliated to French social security system
Exclusion Criteria:
- Other associated neurological condition that could independently affect walking or motor activity
- Inability to wear the sensor device (skin allergy, sensory intolerance)
- Inability to comply with study procedures (cognitive impairment, no fixed domicile)
- Participation in another interventional study during the same period
- Pregnant or breastfeeding women
- Patients under legal protection (guardianship or curatorship)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
CMT1A-HOME
Adult patients diagnosed with CMT1A followed at the National Reference Centre for Rare Peripheral Neuropathies (CHU de Limoges) and/or the Laboratoire d'AQM (Service de MPR, CHU de Limoges).
Participants will undergo: (1) comprehensive in-hospital functional evaluation using the CMT-FOM scale and standard clinical assessments, and (2) home-based physical activity monitoring with ActiGraph LEAP wearable sensors over 7 days.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pearson/Spearman r: daily step count (ActiGraph) vs. CMT-FOM total score
Délai: Day 1 (CMT-FOM)
|
Correlation coefficient (r : -1 to +1) between mean daily step count (steps/day) over 7 days and CMT-FOM total score obtained at Day 1 hospital visit.
|
Day 1 (CMT-FOM)
|
|
Pearson/Spearman r: daily step count (ActiGraph) vs. CMT-FOM total score
Délai: Day 7 (home monitoring)
|
Correlation coefficient (r : -1 to +1) between mean daily step count (steps/day) over 7 days and CMT-FOM total score obtained at Day 1 hospital visit.
|
Day 7 (home monitoring)
|
|
Pearson/Spearman r: daily activity counts (ActiGraph) vs. CMT-FOM total score
Délai: Day 1
|
Correlation coefficient (r : -1 to +1) between mean daily activity counts (raw accelerometry counts/day) over 7 days and CMT-FOM total score.
|
Day 1
|
|
Pearson/Spearman r: daily activity counts (ActiGraph) vs. CMT-FOM total score
Délai: Day 7 (home monitoring)
|
Correlation coefficient (r : -1 to +1) between mean daily activity counts (raw accelerometry counts/day) over 7 days and CMT-FOM total score.
|
Day 7 (home monitoring)
|
|
Pearson/Spearman r: daily sedentary time (ActiGraph) vs. CMT-FOM total score
Délai: Day 1
|
Correlation coefficient (r : -1 to +1) between mean daily sedentary time (minutes/day) over 7 days and CMT-FOM total score.
|
Day 1
|
|
Pearson/Spearman r: daily sedentary time (ActiGraph) vs. CMT-FOM total score
Délai: Day 7 (home monitoring)
|
Correlation coefficient (r : -1 to +1) between mean daily sedentary time (minutes/day) over 7 days and CMT-FOM total score.
|
Day 7 (home monitoring)
|
|
Pearson/Spearman r: composite sensor score vs. CMT-FOM sub-scores
Délai: Day 1
|
Correlation coefficient (r : -1 to +1) between ActiGraph-derived metrics and CMT-FOM sub-domain scores (upper limb, lower limb, balance, endurance).
Reported separately per sub-score.
|
Day 1
|
|
Pearson/Spearman r: composite sensor score vs. CMT-FOM sub-scores
Délai: Day 7 (home monitoring)
|
Correlation coefficients (r : -1 to +1) between ActiGraph-derived metrics and CMT-FOM sub-domain scores (upper limb, lower limb, balance, endurance).
Reported separately per sub-score.
|
Day 7 (home monitoring)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Intraclass Correlation Coefficient (ICC) of daily step count across 7 days
Délai: Day 7 (home monitoring)
|
Test-retest reliability (ICC (0 to 1), two-way mixed, absolute agreement) of daily step count measured by ActiGraph LEAP across 7 home monitoring days.
|
Day 7 (home monitoring)
|
|
Coefficient of Variation (CV, %) of daily activity counts across 7 days
Délai: Day 7 (home monitoring)
|
Day-to-day variability expressed as CV (%) for raw accelerometry activity counts across 7 days.
|
Day 7 (home monitoring)
|
|
Minimal Detectable Change (MDC) of daily step count
Délai: Day 7 (home monitoring)
|
MDC95 of daily step count (steps/day), calculated from SEM and ICC, representing the smallest change exceeding measurement error.
|
Day 7 (home monitoring)
|
|
Pearson r: daily step count vs. CMT Neuropathy Score (CMT-NS)
Délai: Day 1
|
Correlation (r : -1 to +1) between mean daily steps/day and CMT-NS total score at Day 1.
|
Day 1
|
|
Pearson r: daily step count vs. 6-Minute Walk Test distance (meters)
Délai: Day 1
|
Correlation (r : -1 to +1) between mean daily steps/day and 6MWT distance (meters) measured at Day 1.
|
Day 1
|
|
Pearson r: daily step count vs. 10-Meter Walk Test speed (m/s)
Délai: Day 1
|
Correlation (r : -1 to +1) between mean daily steps/day and 10MWT comfortable-pace speed (m/s) at Day 1.
|
Day 1
|
|
Mean daily step count stratified by CMT-FOM severity quartile
Délai: Day 1
|
Mean (±SD) daily step count compared across CMT-FOM severity quartiles (Q1-Q4) to characterise activity profiles by disease severity.
|
Day 1
|
|
Mean daily step count stratified by CMT-FOM severity quartile
Délai: Day 7 (home monitoring)
|
Mean (±SD) daily step count compared across CMT-FOM severity quartiles (Q1-Q4) to characterise activity profiles by disease severity.
|
Day 7 (home monitoring)
|
|
Mean daily sedentary time stratified by CMT-FOM severity quartile
Délai: Day 1
|
Mean (±SD) daily sedentary time (min/day) compared across CMT-FOM severity quartiles.
|
Day 1
|
|
Mean daily sedentary time stratified by CMT-FOM severity quartile
Délai: Day 7 (home monitoring)
|
Mean (±SD) daily sedentary time (min/day) compared across CMT-FOM severity quartiles.
|
Day 7 (home monitoring)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Publications générales
- Tudor-Locke C, Bassett DR Jr. How many steps/day are enough? Preliminary pedometer indices for public health. Sports Med. 2004;34(1):1-8. doi: 10.2165/00007256-200434010-00001.
- Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016 Jun;15(2):155-63. doi: 10.1016/j.jcm.2016.02.012. Epub 2016 Mar 31.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.
- Mandarakas MR, Eichinger KJ, Bray P, Cornett KMD, Shy ME, Reilly MM, Ramdharry GM, Scherer SS, Pareyson D, Estilow T, McKay MJ; for ACT-CMT Study Group; Herrmann DN, Burns J. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure. Neurology. 2024 Feb 13;102(3):e207963. doi: 10.1212/WNL.0000000000207963. Epub 2024 Jan 18.
- Shy ME, et al. CMT Neuropathy Score: a reliable scale of disability for Charcot-Marie-Tooth disease. Neurology. 2005;64(10):1738-1744.
- Vinci P, Perelli SL. Footdrop, foot rotation, and plantarflexor failure in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil. 2002 Apr;83(4):513-6. doi: 10.1053/apmr.2002.31174.
- Tofthagen C, et al. Wearable technology for monitoring physical activity in patients with Charcot-Marie-Tooth disease. J Neurol Sci. 2019;396:102-107.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Maladies génétiques, innées
- Maladies neurodégénératives
- Anomalies congénitales
- Troubles hérédodégénératifs, système nerveux
- Malformations du système nerveux
- Polyneuropathies
- Neuropathie sensorielle et motrice héréditaire
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- Comportement
- Signes et symptômes
- Maladies du système nerveux périphérique
- Limitation de la mobilité
- Maladie de Charcot-Marie-Tooth
- Maladies neuromusculaires
- Activité motrice
Autres numéros d'identification d'étude
- 87RI26_0017_CMT1A-HOME
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .